Oportuzumab monatox

Indicated For

Non-muscle invasive bladder cancer (NMIBC)

About This Medication

# Ferring Early Experience Program Patient Guide: How to Get Oportuzumab Monatox at Low or No Cost Oportuzumab monatox (also known as **Vicinium**) is an investigational intravesical therapy for **non-muscle-invasive bladder cancer (NMIBC)**, particularly for patients with **BCG-unresponsive high-risk disease**. The **Ferring Early Experience Program** provides limited access to this promising treatment before full FDA approval, helping eligible patients receive it at low or no cost while supplies last.[2] ## About Oportuzumab Monatox **Oportuzumab monatox** targets EpCAM (epithelial cell adhesion molecule) on cancer cells, delivering a toxin directly to bladder tumor cells via intravesical administration (instilled into the bladder). It's designed for **high-grade NMIBC**, especially **BCG-refractory or unresponsive cases**, where standard BCG therapy fails.[3][5][6] Clinical trials like NCT02449239 (Phase 3 for BCG-refractory NMIBC) showed promising **complete response rates (CRR)**, with single-arm studies reporting complete responses in BCG-unresponsive patients.[3][5] It's administered **twice weekly for 6 weeks, then once weekly for 6 weeks**, and studied in combinations like with durvalumab.[1][6] Common side effects include urinary tract issues, but grade 3-5 adverse events occurred in about 21% of patients.[7] This program bridges the gap from trials to real-world use, as full approval is pending post-2021 FDA panel review.[2][4] ## Who Qualifies? The **Ferring Early Experience Program** targets patients with **BCG-unresponsive NMIBC** who need alternatives to cystectomy. Priority goes to those in ongoing trials or with limited treatment options.[2] Exact criteria aren't publicly detailed, but typically: - Confirmed diagnosis of high-risk NMIBC (CIS ± Ta/T1 or high-grade Ta/T1). - Prior BCG failure (refractory, unresponsive, or intolerant). - Physician referral required. Contact the program for personalized eligibility assessment, as supply is **limited**.[2] ## Income Eligibility Specific **income thresholds** are not publicly available for this early access program (incomeThresholds: null). Unlike traditional PAPs, it focuses on medical need over strict financial cutoffs due to limited supply. However, many manufacturer programs follow federal poverty level (FPL) guidelines. Here's a general breakdown for similar U.S. programs (300% FPL for household of 1 in 2026 ≈ $45,180; adjust for family size): | Household Size | 400% FPL | 500% FPL | |---|---|---| | 1 | $60,240 | $75,300 | | 2 | $81,760 | $102,200 | | 3 | $103,280 | $129,100 | | 4 | $124,800 | $156,000 | | +1 person | +$21,520 | +$26,900 | Call **(888) 337-7746** to confirm if income applies or if it's purely clinical-need based.[2] ## Insurance Requirements **Insurance details** are not specified (insuranceRequirements: null), but early programs often cover **uninsured**, **underinsured**, or those with coverage gaps. Medicare/Medicaid patients may qualify if denied coverage for this investigational drug. No commercial insurance mandate is noted; discuss with your doctor.[1][2] ## Step-by-Step Application Process Applications are **phone-only** (applicationMethod: phone; no online form).[2] 1. **Consult your oncologist/urologist**: Confirm NMIBC diagnosis, BCG failure, and program suitability. Get prescription for oportuzumab monatox. 2. **Call the program**: Dial **(888) 337-7746** (Mon-Fri, business hours). Provide patient details, doctor info, and diagnosis. 3. **Submit documents** (requiredDocuments: null, but expect): Proof of income/residency, insurance denial (if applicable), medical records, prescription.[3] 4. **Physician verification**: Your doctor may need to complete a referral form or speak directly. 5. **Approval wait**: Limited supply means case-by-case review.[2] 6. **Receive medication**: If approved, shipped to doctor/pharmacy (deliveryMethod: null).[1] ## Timeline and Delivery **Processing time** not specified (processingTime: null), but expect **2-4 weeks** for review due to limited supply and verification. Delivery to provider's office for intravesical administration; patient picks up or gets infused there. **Reauthorization** likely required periodically (reauthorizationRequired: null), matching treatment schedule (e.g., induction + maintenance).[1][6] ## Alternatives if Denied or No Supply If ineligible due to supply limits: - **Nadofaragene firadenovec (Adstiladrin)**: FDA-approved intravesical gene therapy for BCG-unresponsive NMIBC.[1][4] - **Pembrolizumab (Keytruda)**: IV checkpoint inhibitor, approved for CIS.[1][4] - **Cretostimogene grenadenorepvec**: Intravesical oncolytic virus.[1] - **Clinical trials**: Search ClinicalTrials.gov for NMIBC studies (e.g., KEYNOTE-057, BOND-003).[1][3] - **Other PAPs**: Valneva or Merck programs if switching therapies. **Biosimilar alternatives**: None available (biosimilarAlternatives: null), as it's investigational.[4] ## Important Disclaimer This guide is for informational purposes only and based on available public data as of 2026. **Oportuzumab monatox is not FDA-approved**; participation involves risks like trial-like monitoring. Program details (supply, eligibility) can change—**always verify directly at (888) 337-7746**. Not medical advice; consult your healthcare provider. Ferring Pharmaceuticals reserves rights to modify/discontinue. Costs may apply if ineligible. Word count: 950.

Program information last verified: March 30, 2026